# US 2019/0315836 A1 · Albumin variants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315836 A1
- Document ID: US20190315836A1
- Status: Published application
- Kind: A1
- Application number: 16/403,862
- Filed: 2019-05-06
- Published: 2019-10-17
- Earliest claimed: 2012-03-16
- Assignees: Albumedix Ltd
- Applicants: Albumedix Ltd
- Inventors: Karen Ann Delahay
- Web page: https://patentgrep.com/patent/US20190315836A1

## CPC

- C07K 14/765: Serum albumin, e.g. HSA
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

## Claims

### Claim 1

(canceled)

### Claim 2

A conjugate comprising:
a polypeptide comprising an albumin having an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 2 and having a substitution in Domain I of said albumin and having a substitution in Domain III of said albumin relative to the amino acid sequence set forth in SEQ ID NO: 2, wherein said albumin has an increased binding affinity to FcRn relative to the binding affinity of an albumin comprising the amino acid sequence of SEQ ID NO: 2 to FcRn, and wherein said substitution in Domain I is selected from amino acids corresponding to positions 82, 83, 111, 112, or any combination thereof of the amino acid sequence of SEQ ID NO: 2 and said substitution in Domain III is selected from amino acids corresponding to positions 425, 505, 510, 512, 524, 527, 531, 534, 569, 573, 575, or any combination thereof of the amino acid sequence of SEQ ID NO: 2; and
a conjugation partner.

### Claim 3 (depends on 2)

The conjugate of claim 2, wherein the conjugation partner is a therapeutic, prophylactic, diagnostic, imaging, or other moiety.

### Claim 4 (depends on 2)

The conjugate of claim 2, wherein the polypeptide comprises substitutions at amino acids corresponding to positions (a) 111 and 573; (b) 82 and 83; (c) 82 and 111; (d) 82 and 112; (e) 82 and 573; (f) 83 and 111; (g) 83 and 112; (h) 83 and 573; (i) 111 and 112; (j) 83, 111, and 573; (k) 112 and 573; (l) 82, 83, and 111; (m) 82, 83, and 112; (n) 82, 83, and 573; (o) 82, 111, and 112; (p) 82, 111, and 573; (q) 82, 112, and 573; (r) 83, 111, and 112; (s) 83, 112, and 573; (t) 111, 112, and 573; (u) 82, 83, 111, and 112; (v) 82, 83, 111, and 573; (w) 82, 83, 112, and 573; (x) 82, 111, 112, and 573; (y) 83, 111, 112, and 573; or (z) 82, 83, 111, 112, and 573 of the amino acid sequence of SEQ ID NO: 2.

### Claim 5 (depends on 2)

The conjugate of claim 2, wherein said substitution in Domain I is selected from amino acids corresponding to positions 83 or 111 of the amino acid sequence of SEQ ID NO: 2.

### Claim 6 (depends on 2)

The conjugate of claim 2, wherein said substitution in Domain III is at the amino acid corresponding to position 573 of the amino acid sequence of SEQ ID NO: 2.

### Claim 7 (depends on 2)

The conjugate of claim 2, wherein said substitution in Domain I is at the amino acid corresponding to position 83 of the amino acid sequence of SEQ ID NO: 2 and wherein said substitution is an asparagine, lysine, or serine.

### Claim 8 (depends on 2)

The conjugate of claim 2, wherein said substitution in Domain I is at the amino acid corresponding to position 111 of the amino acid sequence of SEQ ID NO: 2 and wherein said substitution is an aspartic acid, glycine, histidine, arginine, glutamine, or glutamic acid.

### Claim 9 (depends on 2)

The conjugate of claim 2, wherein said substitution in Domain III is at the amino acid corresponding to position 573 of the amino acid sequence of SEQ ID NO: 2 and wherein said substitution is a proline, tyrosine, tryptophan, histidine, phenylalanine, threonine, isoleucine, or valine.

### Claim 10 (depends on 2)

The conjugate of claim 2, wherein said substitution in Domain III is at the amino acid corresponding to position 573 of the amino acid sequence of SEQ ID NO: 2 and wherein said substitution is a proline, tyrosine, or tryptophan.

### Claim 11 (depends on 2)

The conjugate of claim 2, wherein said substitution in Domain III is the amino acid corresponding to at position 573 of the amino acid sequence of SEQ ID NO: 2 and wherein said substitution is a proline.

### Claim 12 (depends on 2)

The conjugate of claim 2, wherein the polypeptide has an increased plasma half-life compared with the half-life of the albumin comprising the amino acid sequence of SEQ ID NO: 2.

### Claim 13 (depends on 2)

The conjugate of claim 2, wherein said polypeptide has a stronger binding affinity to FcRn and optionally, a longer plasma half-life relative to a polypeptide comprising the amino acid sequence of SEQ ID NO: 2.

### Claim 14 (depends on 2)

The conjugate of claim 2, wherein the polypeptide comprises substitutions at amino acids corresponding to positions 111 and 573 of the amino acid sequence of SEQ ID NO: 2.

### Claim 15 (depends on 2)

The conjugate of claim 2, wherein the polypeptide comprises substitutions at amino acids corresponding to positions 83, 111, and 573 of the amino acid sequence of SEQ ID NO: 2.

### Claim 16 (depends on 2)

The conjugate of claim 2, wherein the polypeptide comprises substitutions at amino acids corresponding to positions 82, 111, and 573 of the amino acid sequence of SEQ ID NO: 2.

### Claim 17 (depends on 2)

The conjugate of claim 2, wherein the polypeptide comprises substitutions at amino acids corresponding to positions 111, 112, and 573 of the amino acid sequence of SEQ ID NO: 2.

### Claim 18 (depends on 2)

The conjugate of claim 2, wherein the polypeptide comprises substitutions at amino acids corresponding to positions 82, 83, 111, and 573 of the amino acid sequence of SEQ ID NO: 2.

### Claim 19 (depends on 2)

The conjugate of claim 2, wherein the polypeptide comprises substitutions at amino acids corresponding to positions 82, 111, 112, and 573 of the amino acid sequence of SEQ ID NO: 2.

### Claim 20 (depends on 2)

The conjugate of claim 2, wherein the polypeptide comprises substitutions at amino acids corresponding to positions 83, 111, 112, and 573 of the amino acid sequence of SEQ ID NO: 2.

### Claim 21 (depends on 2)

The conjugate of claim 2, wherein the polypeptide comprises substitutions at amino acids corresponding to positions 82, 83, 111, 112, and 573 of the amino acid sequence of SEQ ID NO: 2.

### Claim 22 (depends on 2)

The conjugate of claim 2, wherein said substitution in Domain I is at the amino acid corresponding to position 83 of the amino acid sequence SEQ ID NO: 2 and wherein said substitution is an asparagine.

### Claim 23 (depends on 2)

The conjugate of claim 2, wherein said substitution in Domain I is at the amino acid corresponding to position 83 of the amino acid sequence of SEQ ID NO: 2 and wherein said substitution is a lysine.

### Claim 24 (depends on 2)

The conjugate of claim 2, wherein the said substitution in Domain I is at the amino acid corresponding to position 111 of the amino acid sequence of SEQ ID NO: 2 and, wherein said substitution is a glutamic acid.

### Claim 25 (depends on 2)

The conjugate of claim 2, wherein said substitution in Domain I is at the amino acid corresponding to positions 83 of the amino acid sequence of SEQ ID NO: 2 and wherein said substitution is a lysine or asparagine, and the said substitution in Domain III is at the amino acid corresponding to position 573 of the amino acid sequence of SEQ ID NO: 2 and wherein said substitution is a proline.

### Claim 26 (depends on 2)

The conjugate of claim 2, wherein said substitutions in Domain I are at the amino acids corresponding to positions 83 and 111 of the amino acid sequence of SEQ ID NO: 2 and wherein said substitutions are an asparagine and a glutamic acid, respectively, and the said substitution in Domain III is at the amino acid corresponding to position 573 of the amino acid sequence of SEQ ID NO: 2 and wherein said substitution is a proline.

### Claim 27

A method of producing a conjugate comprising:
providing an albumin having an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 2 and having a substitution in Domain I of said albumin and having a substitution in Domain III of said albumin relative to the amino acid sequence set forth in SEQ ID NO: 2, wherein said albumin has an increased binding affinity to FcRn relative to the binding affinity of an albumin comprising the amino acid sequence of SEQ ID NO: 2 to FcRn, and wherein said substitution in Domain I is selected from amino acids corresponding to positions 82, 83, 111, 112, or any combination thereof of the amino acid sequence of SEQ ID NO: 2 and said substitution in Domain III is selected from amino acids corresponding to positions 425, 505, 510, 512, 524, 527, 531, 534, 569, 573, 575, or any combination thereof of the amino acid sequence of SEQ ID NO: 2; and
conjugating the albumin to a conjugation partner selected from a therapeutic, prophylactic, diagnostic, imaging or other moiety.
